Clinical Trials Sponsored by Berlex Foundation

Total 18791 results

Vertex Pharmaceuticals Incorporated

Completed

A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom
University of Bergen

Completed

Light Treatment to Shift-working Nurses

Shift-Work Sleep Disorder

Norway
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, France, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

Australia, United Kingdom
University of Bergen

Completed

Cognitive Functional Therapy Compared to Cognitive Patient Education and Physiotherapy for Patients With Low Back Pain (FAktA)

Low Back Pain

Norway
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Cystic Fibrosis

United Kingdom, Canada, Australia
University of Bergen

Unknown

Effectiveness of Three Different Oral Moisturizers in Palliative Care Patients.

Xerostomia

Norway
Vertex Pharmaceuticals Incorporated

Completed

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

Cystic Fibrosis

Netherlands
University of Bergen

Completed

Therapy Light Rooms for Improved Sleep in Dementia Patients (DEMLIGHT)

Dementia | Sleep Fragmentation | Behavioural and Psychiatric Symptoms of Dementia

Norway
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects

Cystic Fibrosis

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

United States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
University of Bergen

Completed

Efficacy of Pain Treatment on Depression in Patients With Dementia (DEP-PAIN-DEM)

Depression | Pain | Dementia

Norway
Vertex Pharmaceuticals Incorporated

Completed

A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus

Influenza Virus

United Kingdom
University of Bergen

Completed

The Effect of Integrating CAMH Into PHC and Traditional Healers' Practice in Uganda: a Randomized Controlled Trial

Community Mental Health Services
Vertex Pharmaceuticals Incorporated

Completed

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

Spinal Cord Injury

United States, Canada
University of Bergen

Completed

Differentiation Induction in Acute Myelogenous Leukemia

Acute Myelogenous Leukemia

Norway
University of Bergen

Unknown

Treatment of Acute Leukemia Relapse After Allotransplantation

Acute Myeloid Leukemia

Norway
Vertex Pharmaceuticals Incorporated

Completed

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Rheumatoid Arthritis

United States, Denmark, Estonia, Lithuania, Netherlands, South Africa
Helse-Bergen HF

Completed

Does a Safety Guidewire Increase the Forces Needed to Move the Ureteroscope up and Down the Ureter?

Ureteroscopy

Norway
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Hepatitis C

United States, Canada, Germany, Puerto Rico, Spain
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Chronic Hepatitis C Virus

United States, United Kingdom, Canada, Germany, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Hepatitis C

United States, Canada, Netherlands, Puerto Rico, Germany
Vertex Pharmaceuticals Incorporated

Completed

An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

Partial Epilepsy

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

Cystic Fibrosis

United States
Freie Universität Berlin

Completed

Online Program Assisting Lifestyle Changes (Asterix 1.0 & Obelix 2.0) (OPAL)

Diabetes Mellitus, Type 2

Germany
Berlin Heart, Inc

Unknown

Berlin Heart EXCOR Pediatric Post Approval Study

Severe Isolated Left Ventricular Dysfunction | Severe Biventricular Dysfunction
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Chronic Hepatitis C

United States
Biolex Therapeutics, Inc.

Completed

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C (PLUS)

Hepatitis C

United States
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

Cystic Fibrosis

United States
University of Bergen

Completed

Therapy for Chronic Cold Agglutinin Disease

Cold Agglutinin Disease

Norway, Russian Federation
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 and Rifampin in Healthy Male Subjects

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Cystic Fibrosis

Netherlands
University of Bergen

Completed

Treatment for Mild Hip Dysplasia in Newborns

Developmental Dysplasia of the Hip
Vertex Pharmaceuticals Incorporated

Completed

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

Hepatitis | Hepatitis C

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Rheumatoid Arthritis

Poland, Croatia, Russian Federation, Bulgaria, Czech Republic, Former Serbia and Montenegro, Slovakia, Slovenia, Ukraine
Vertex Pharmaceuticals Incorporated

Completed

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Rheumatoid Arthritis

Bulgaria, Croatia, Former Serbia and Montenegro, Poland, Russian Federation, Slovenia
Mylan Bertek Pharmaceuticals

Completed

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

Hypertension

United States
Charite University, Berlin, Germany
German Research Foundation; Hannover Medical School; Ruhr University of Bochum

Terminated

Energy Turnover in Patients With Anorexia Nervosa

Anorexia Nervosa

Germany
Vertex Pharmaceuticals Incorporated

Recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Berlin Heart, Inc

Recruiting

EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study

Heart Failure | Congenital Heart Disease | Transplant; Failure, Heart

United States
Vertex Pharmaceuticals Incorporated

Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

Proteinuric Kidney Disease

United States, Spain, Ghana, France, United Kingdom, Belgium, Brazil, Colombia, Portugal, Canada, Puerto Rico, Netherlands
Vertex Pharmaceuticals Incorporated

Recruiting

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Impaired Hypoglycemic Awareness | Severe Hypoglycemia

United States, Norway, Italy, Canada, France, United Kingdom, Switzerland, Netherlands, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, United Kingdom, New Zealand, Israel, Australia, Ireland, Germany, Sweden, Czechia, Portugal, Hungary
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults

Pain

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Pain

United States

Clinical Trials Sponsored by Berlex Foundation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations